Accéder au contenu
Merck
Toutes les photos(1)

Documents

1680007

USP

Triamterene

United States Pharmacopeia (USP) Reference Standard

Synonyme(s) :

2,4,7-Triamino-6-phenylpteridine, 6-Phenyl-2,4,7-pteridinetriamine

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C12H11N7
Numéro CAS:
396-01-0
Poids moléculaire :
253.26
Numéro MDL:
MFCD00006708
Code UNSPSC :
41116107
ID de substance PubChem :
329751381
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

triamterene

Fabricant/nom de marque

USP

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1

InChI

1S/C12H11N7/c13-9-7(6-4-2-1-3-5-6)16-8-10(14)18-12(15)19-11(8)17-9/h1-5H,(H6,13,14,15,17,18,19)

Clé InChI

FNYLWPVRPXGIIP-UHFFFAOYSA-N

Informations sur le gène

human ... SCNN1A(6337) , SCNN1B(6338) , SCNN1G(6340)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Triamterene USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Triamterene and Hydrochlorothiazide Capsules
  • Triamterene and Hydrochlorothiazide Tablets
  • Triamterene Capsules

Remarque sur l'analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Autres remarques

Sales restrictions may apply.

Pictogrammes

Exclamation mark
GHS07

Mention d'avertissement

Warning

Mentions de danger

H302,H315,H319,H335

Classification des risques

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Organes cibles

Respiratory system

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

[Pharmacology of potassium-sparing diuretics: amiloride and triamterene].
G Rorive et al.
Coeur et medecine interne, 17(2), 207-215 (1978-04-01)
A Haris et al.
Orvosi hetilap, 137(35), 1907-1914 (1996-09-01)
The group of drugs, so-called "potassium sparing diuretics" represent an important part of our modern therapeutic arsenal. Their "weak diuretic" properties are especially beneficial in cirrhotic patients with ascites, when highly effective loop diuretics may be hazardous. Potassium sparing diuretics
H Priewer et al.
Die Pharmazie, 52(3), 179-181 (1997-03-01)
This work represents a summary of studies carried out with potassium and magnesium retaining triamterene derivatives. The synthesis, analytics and physico-chemical characteristics of those substances are described. Furthermore, the relationships between the chemical structure and electrolyte excretion, pharmacokinetics, metabolism and
C Lucas et al.
Journal d'urologie, 88(1), 37-42 (1982-01-01)
Various studies have demonstrated a relationship between nephrolithiasis and the ingestion of certain drugs. We are particularly interested in the effects of triamterene. Five published case studies on patients of both sexes between 43 and 60 years of age have
R A Carey et al.
Clinical therapeutics, 6(3), 302-309 (1984-01-01)
A small number of patients taking products containing triamterene (TAT) develop renal calculi that contain TAT and its metabolites. Most TAT-containing calculi are composed of various crystalline materials, but a small number consist only of TAT, its metabolites, and a
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique